Register for our EIS fund today

A passion for

innovation

We are constantly innovating our people, project management and technology models leading to outstanding results for our collaborators. The world’s first app based technology platform Chemistry in the CloudTM enables us to work together to make faster decisions. Our deep understanding that an early and intensive evaluation of target molecules based on real insight into the science will lead to faster downstream execution. The result is a higher throughput of successful drug-like compounds.

Organic chemistry

o2h is a highly reputed service provider of mg/g scale discovery chemistry. We have partnered with a range of well known pharmaceutical and biotechnology companies from Europe, USA and Japan.

The specialised team at o2h has a broad array of experience in preparing small molecule NCEs with the requisite high quality specifications. It is proficient in utilising perse methodologies, including the synthesis of singles, multi-step, small arrays as well as focused libraries. Our scientific team is also experienced in parallel construction of focused libraries for use in hit-to-lead and lead optimisation projects.

The delivery of all our compounds is accompanied with complete characterisation data including, but not limited to, high-field NMR, mass and purity by LC-MS/HPLC/GC.

Access to databases such as SciFinder and Beilstein provides the team with all the necessary current information to modify and develop new synthetic routes.

o2h has experience of a wide range of chemistry including:

  • Chiral chemistry
  • Aliphatic, aromatic and heterocyclic chemistry
  • Carbohydrate chemistry
  • Peptide chemistry
  • Steroid chemistry
  • Nucleoside chemistry
  • Combinatorial chemistry
  • Natural product chemistry
  • Fragment libraries
  • Metabolite/impurity/reference synthesis
  • Microwave chemistry

Medicinal chemistry

Medicinal chemistry expertise available at o2h includes hit identification, hit-to-lead optimisation, lead generation, and lead optimisation. All of these can be accessed as stand-alones or as a part of an integrated drug discovery project.

Hit identification/lead generation projects have involved ligand design for customer-defined targets, synthesis of homologous or diverse series of compounds, design and generation of structurally related compounds, combinatorial synthesis of general as well as focused libraries and search for surrogates of core chemical scaffolds.

Hit-to-lead projects typically involve confirmation of a genuine structure-activity relationship (SAR) and reducing structural/pharmacological liabilities. o2h has the capability to synthesise small focused arrays of compounds in sufficient quantities to allow clients to rapidly screen these compounds for ADME and in vitro biological activity (primary as well as secondary screenings).

For projects advancing to lead optimisation phase, chemists at o2h work intensively with their biology counterparts to produce compounds which closely match the desired target product profile. Typically, this involves a thorough search of prior art and assuring patentability, generation of back-up series and leading the compounds to in vivo proof-of-concept. Our biologists can assist in generating in vivo experimental models recapitulating a particular human pathological condition, designing and efficiently executing PK/PD, toxicology and other relevant pharmacological studies to advance these compounds further.

Computational chemistry

Computational chemists at o2h work at providing stand-alone services to our clients with in silico based screening projects as well as supporting medicinal chemistry projects. Computational chemistry expertise includes molecular modelling, virtual screening and drug designing.

Virtual screening services include target identification, in silico drug-likeness, screening of client/commercial databases to identify focused lead/hit compounds and docking studies to prioritise hits for in vitro studies.

Drug designing to support hit generation and lead optimisation are applied to augment medicinal chemistry design efforts and help guide structural modifications to enhance potency, selectivity and drug-like characteristics. Close cooperation between our molecular modellers and medicinal chemists plays a vital role in this process.

Apart from these, we also support designing target-focused libraries, target modelling, molecular dynamic simulations and developing highly predictive 3D-QSAR models based on target and therapeutic areas.

Chemical biology

o2h has recently expanded its capability to support several chemical biology projects to deliver bespoke, high quality tools to positively impact target validation and mechanistic understanding.

This includes cutting edge research to prepare key diverse intermediates alongside developing optimised construction methods to prepare these complex molecules in the most efficient manner. The involvement of our analytical group plays an essential role to ensure these tools are isolated in the most appropriate way to meet the required compound specifications and deliver high quality biological data.

Antibody drug conjugate

adc-dicvory1

Bespoke Intermediates for ADCs 

Building on our expertise to support small molecules drug discovery programs, we have now extended our service offering to projects in ADC space as outlined below.

Our service offering includes the synthesis, development and scale-up of bespoke Linker, Linker-Reagent, Reagents, Peptide scaffolds, and associated intermediates to meet our collaborator's specifications for their R&D needs.

Discovery News

22 Jun 2018

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage. PhoreMost has built a pipeline of novel targets and early drug discovery programmes using its next-generation “SITESEEKER®” phenotypic screening platform. The collaboration will see o2h deploy its expertise in medicinal chemistry to help progress PhoreMost’s portfolio rapidly through the hit-to-lead and lead-optimisation stages of drug discovery. Dr Chris Torrance CEO of PhoreMost, said: “Since its inception, PhoreMost’s model has been to forge a new approach to drug discovery, working collaboratively with partners in order to progress new medicines. The alliance with o2h truly reflects this, and represents an important step in our mission to bring a greater diversity of therapies to patients, more quickly and at affordable prices.”  We have been impressed by the ability of PhoreMost’s SITESEEKER platform to systematically identify first-in-class drug targets in areas of high unmet need, and are excited to be applying our highly complementary capabilities to develop these potentially high value programs,” said Sunil Shah, CEO of o2h discovery: “Our shared vision of working collaboratively is also a testament to the strength of the Cambridge UK Biotech cluster for discovery and progressing the next generation of therapeutics.” PhoreMost recently announced the completion of an £11m ($15m) Series-A investment round. The investment will be used to expand operations on the Babraham Research Campus and progress several novel drug targets from its next-generation “SITESEEKER” phenotypic screening platform into first-in-class drug discovery programmes. Press Link - Phoremost and o2h Discovery

18 Apr 2018

Curza Global, LLC and O2H DISCOVERY (O2H) are pleased to announce a multi FTE chemistry collaboration to support Curza as it drives its lead program targeting dram negative through lead optimization and towards the clinic. Curza’s lead program is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome. o2h is pleased to collaborate with industry leader, Curza, to tackle the rapid and global spread of antimicrobial resistance. Working through different pathways Curza hopes to design effective new drugs to tackle gram-negative infections The approach Curza has taken is unique and management is very focused to ensure their drug makes its way to patients quickly. Sunil Shah, CEO of O2h “The rapid and global spread of antimicrobial-resistant organisms in recent years has been unprecedented. Although resistant Gram-positive infections have been concerning to clinicians, the increasing incidence of antibiotic-resistant Gram-negative infections have become the most pressing issue in bacterial resistance.” Ryan Davies, CEO of Curza “We are very happy to be working with O2h on this program. We wanted to make fast progress with this project and O2h’s focus on execution speed is a key reason why we selected them to work on our highest priority project. About O2h: o2h seeds new ideas in science, technology and social enterprise. We work across boundaries and take a collaborative and shared approach to innovation, and therefore we co-invest, co-create and co-execute to bring these ideas to life. o2h discovery is an integrated chemistry and biology services capability for collaborative research and o2h ventures supports early stage life science assets through seed investment. o2h is organized into 6 verticals including discovery, ventures, technology, therapeutics, co-work and community, and is co-located in Ahmedabad, India and in Cambridge UK. Please see www.o2h.com for more details. About Curza: Curza is a Utah-based drug development company focused on developing novel therapeutics to control antibiotic resistant bacteria. With original technology licensed from the University of Utah, Curza is in the early stages of developing two novel classes of antibiotics. Headquartered in Salt Lake City, UT with offices in Cambridge, MA, Curza is privately held and backed by Clarke Capital Partners and other private investors. Please visit www.curza.com for more information.

02 Nov 2017

The quest to positively benefit the lives of patients in the world of drug discovery means finding novel therapeutics for unmet medical needs. The biotech and pharma companies have been increasingly resorting to external innovation to supplement their pipeline of ideas and turbocharge their research-based businesses with enterprising partners with complementary ideas, capabilities and services. It is therefore hardly surprising that the top medicinal chemists working in both large and small companies have multiple partners across different continents and time-zones. To deliver these iterative discovery projects often entails detailed co-ordination of inter-related activities and extensive multi-tasking. Project management is the hub that allows these complex matrices of networks to communicate and for the project to successfully advance. In today’s fast paced and technologically advanced digital world, providing the project manager the right tools to make informed decisions is key to successful delivery. o2h Discovery’s innovative app Chemistry in the Cloud TM builds upon the latest advances in secure cloud-based mobile technology and integrates project management of external drug discovery programs. The app enables communication between the various scientific stakeholders essential to successful project advancement leading to faster decision making. It negates the onerous tasks of weeding out critical information that is required to take a complex decision by extracting the information from large data intensive reports and databases. These crucial decision points are now just a ‘tap/swipe-of-the-finger’ in the Chemistry in the CloudTM app so that they can speedily execute tasks anytime, anywhere. The communication covering a gamut of research activities in relation to process of research now truly happens in 24/7 real-time. o2h announced a worldwide launch and first live demonstration of our revolutionary project management app – Chemistry in the Cloud TM on 10th September 2017 at the 19th RSC/SCI Cambridge medicinal chemistry conference to some of world’s top scientists. The app’s full suite of project management tools is available exclusively to live project collaborators and a lighter version is open for researchers looking for a quote for the synthesis of small molecules. https://www.linkedin.com/in/sunil-shah-4bb225/detail/recent-activity/shares/ Nilesh Dagia (nilesh@o2h.com) is the COO @ o2h Discovery

@o2hventures

September 15th 2018 09:09:07

o2h is celebrating women’s open day on 22nd Sept ‘18 to inspire women in science, technology and enterprise https://t.co/HfDyStxUz1

@o2hventures

June 10th 2018 03:06:53

RT @OxDrugDes: Paul is at #ASMicrobe this week, track him down if you want to find out more about our exciting #antibiotics projects! #ASMm…

@o2hventures

June 4th 2018 05:06:22

RT @CJBS_VCW: Third place, Eye Bot, with Prashant Shah, Director of @o2hventures #CamVCW https://t.co/4hHXQfFKkt

@o2hventures

June 4th 2018 03:06:22

RT @JamieQuested: Great flight with @primeraair from @STN_Airport to Boston for #BIO2018. Strong East of England presence at this year’s co…

@o2hventures

June 2nd 2018 11:06:46

RT @CJBS_VCW: Our third judge is Prashant Shah
Director at @o2hventures . Having begun a career with the Strategy group at Accenture he bec…

@o2hventures

June 2nd 2018 11:06:15

RT @CJBS_VCW: And we’re off. Full house for our keynote speaker Sunil Shah, founder of @o2hventures #biotech #Healthcare https://t.co/CHplg

@o2hventures

June 2nd 2018 11:06:45

RT @CJBS_EC: Nurturing great British therapeutics #innovation : we're delighted to launch our Venture Creation Weekend in #biotech and #hea…

@o2hventures

May 11th 2018 12:05:23

https://t.co/4BDPRCZlZ0

@o2hventures

May 9th 2018 11:05:05

Thanks for your support business weekly, it is going to be a challenge to get this site working again but honestly… https://t.co/htfsNxBEO9

@o2hventures

May 8th 2018 05:05:11

o2h acquires 2.76 acre heritage Hauxton Mill site, Cambridge, UK with plans to develop it into the o2h SciTech Park https://t.co/zID1XshZp7

o2h culture, people & careers

Subscribe to our newsletter